Claritas Pharmaceuticals Inc V.CLAS.H

BEETLEBUNG Salzman Isreal Company???

[WORKINMONTANA]

Can someone explain to my why the market does not like the fact that Kalytera hired, funds pays Salzman research for Beetlbung Pharma?  Wouldn’t money made by Salzman be used to fund their parent company BEETLEBUNG to progress all the options to acquire the rights to all the CBD formulations that they have developed for Kalyteras ?

Secondly, when is Aurora going to make an offer?  They already have a study a McGill University for  chronic pain,  which Kalytera already obtained the rights to market from Beetlebung? LINK https://globenewswire.com/news-release/2018/11/20/1654543/0/en/The-Future-of-CBD-for-Pain-Treatment-and-Sports-Medicine-Orion-Nutraceuticals-Inc-CSE-ORI-Aurora-Cannabis-Inc-CannTrust-Holdings-Inc-Kalytera-Therapeutics.html

Beetlebung Pharma Limited (BPL), an Israeli affiliate of the Salzman Group, focuses on the discovery and development of novel cannabis-related pharmaceutical therapeutics. The Salzman Group provides clinical management and other services to Kalytera in connection with Kalytera’s programs evaluating CBD in the prevention and treatment of graft versus host disease. BPL has invented a broad range of cannabinoid new chemical entities in therapeutic areas encompassing pain, inflammation, autoimmunity, ischemia-reperfusion injury, trauma, and central nervous system injury. BPL is also active in the development of novel formulations of existing cannabinoids, terpenes, and sesquiterpenes that may contribute to the entourage effect. To provide scientific support for its pharmaceutical programs, BPL carries out biological research on terpenoid cell signaling and pharmacology in its basic research laboratories. BPL is a private, closely held corporation.


“Under this agreement, Kalytera will have the option to license from BPL certain proprietary medical cannabis formulations, which can initially be brought to market in jurisdictions that have already approved access to cannabis for medical purposes. Kalytera believes that this will provide a more near-term path to revenues, compared with the lengthier process required for commercialization following FDA approval.”(https://www.businesswire.com/news/home/20180719005240/en/Kalytera-Enter-Medical-Cannabis-Market-Focus-Treatment)


Like what’s the hold up with the SP rocketing up?  This will fly faster than $SX IMO